Compare Amylx Pharmaceuticals Inc (AMLX) vs Kinder Morgan Inc (KMI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Kinder Morgan Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Kinder Morgan Inc trades at $32.32 (market cap $71.46B). The key difference: Kinder Morgan Inc is far larger — about 36.1× Amylx Pharmaceuticals Inc's market cap, and Kinder Morgan Inc pays a 3.66% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | KMI | |
|---|---|---|
Market Cap | $1.98B | $71.46B |
Sector | Health | Energy |
52-Week High | $18.70 | $34.31 |
52-Week Low | $7.64 | $25.84 |
Enterprise Value | $1.70B | $103.34B |
Dividend Yield | — | 3.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Kinder Morgan (KMI) trades at $32.12, down 0.86% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 2026 earnings, beating estimates with $0.48 EPS, and maintains a solid dividend. Revenue grew to $16.94B in 2025, with net income margin improving to 18.92%. Recent news highlights KMI's exposure to natural gas infrastructure growth and stable cash flows from fee-based contracts.
KMI offers a balanced risk-reward profile with steady cash flow and dividend appeal, supported by a $10.1B project backlog. Risks include commodity price volatility and high debt levels. Analyst consensus is mixed but leans positive, with 47% buy ratings. The stock's valuation at a P/E of 21.56 is reasonable given earnings growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →
